Pernix appoints Leung to board of directors

Pernix Therapeutics Holdings Inc., a pharmaceutical company specializing in pain and central nervous system conditions, recently appointed Gabriel Leung to its board of directors.
Leung will also chair the nominating committee and serve on the audit and compensation committee.
“I’m very pleased to welcome Mr. Leung to the Board,” Chairman and CEO John Sedor said in a news release. “His strong background in pharmaceutical business and strategy, industry relationships and established track record of helping to increase shareholder value will be invaluable to Pernix and its shareholders.”
Leung was most recently vice chair and board member of NovoCure Ltd., a publicly listed oncology company working on a proprietary therapy for the treatment of solid tumor cancers. From 2003-10, Leung oversaw OSI Pharmaceutical Inc.’s Oncology and Diabetes Business. Prior to that, he acted as group vice president of the global prescription business at Pharmacia Corp.
Leung earned a bachelor of science in pharmacy with high honors from the University of Texas and a master of science in pharmacy from the University of Wisconsin, where he concentrated in pharmaceutical marketing.